Tracey L. Evans

7.2k total citations · 2 hit papers
107 papers, 4.0k citations indexed

About

Tracey L. Evans is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Tracey L. Evans has authored 107 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pulmonary and Respiratory Medicine, 58 papers in Oncology and 15 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Tracey L. Evans's work include Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Diagnosis and Treatment (25 papers) and Lung Cancer Research Studies (24 papers). Tracey L. Evans is often cited by papers focused on Lung Cancer Treatments and Mutations (54 papers), Lung Cancer Diagnosis and Treatment (25 papers) and Lung Cancer Research Studies (24 papers). Tracey L. Evans collaborates with scholars based in United States, Australia and Canada. Tracey L. Evans's co-authors include Corey J. Langer, Thomas J. Lynch, Charu Aggarwal, Joshua Bauml, Roger B. Cohen, Lecia V. Sequist, Christine Ciunci, Pasi A. Jänne, Roslyn N. Boyd and Alona Muzikansky and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Tracey L. Evans

106 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

2008 661 citations Lecia V. Sequist, Alexander I. Spira et al. Journal of Clinical Oncology profile →
Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

2017 387 citations Stephen Bagley, Shawn Kothari et al. profile →

Peers

Countries citing papers authored by Tracey L. Evans

Since Specialization

Citations

This map shows the geographic impact of Tracey L. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tracey L. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tracey L. Evans more than expected).

Fields of papers citing papers by Tracey L. Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tracey L. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tracey L. Evans. The network helps show where Tracey L. Evans may publish in the future.

Co-authorship network of co-authors of Tracey L. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Tracey L. Evans. A scholar is included among the top collaborators of Tracey L. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tracey L. Evans. Tracey L. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PREdiction and Diagnosis using Imaging and Clinical biomarkers Trial in Traumatic Brain Injury (PREDICT-TBI) study protocol: an observational, prospective, multicentre cohort study for the prediction of outcome in moderate-to-severe TBI 2023 ·BMJ Open ·Fatima Nasrallah, Judith Bellapart, James Walsham, (unknown), Xuan Vinh To, Silvia Manzanero, Nathan J. Brown, Jason Meyer, Janine Stuart, Tracey L. Evans, Shekhar S. Chandra, Jason P. Ross, Lewis Campbell, Siva Senthuran, Virginia Newcombe, James P. McCullough, Jennifer Fleming, (unknown), Michael C. Reade	6
2	Global trends in TVET: A framework for social justice 2019 ·Tracey L. Evans	25
3	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer 2018 ·Journal of Clinical Oncology ·Nathan A. Pennell, Joel W. Neal, Jamie E. Chaft, Christopher G. Azzoli, Pasi A. Jänne, Ramaswamy Govindan, Tracey L. Evans, Daniel B. Costa, Heather A. Wakelee, Rebecca S. Heist, Marc A. Shapiro, Alona Muzikansky, Sudish C. Murthy, Michael Lanuti, Valerie W. Rusch, Mark G. Kris, Lecia V. Sequist	137
4	Palliative Care in Lung Cancer: When to Start 2018 ·Current Oncology Reports ·Prianka Bhattacharya, Scott Dessain, Tracey L. Evans	12
5	OA07.01 Phase II Study of Pembrolizumab for Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT) 2018 ·Journal of Thoracic Oncology ·(unknown), (unknown), Christine Ciunci, Charu Aggarwal, Christiana Davis, Tracey L. Evans, Charuhas Deshpande, Linda Miller, Prakash A. Patel, Evan Alley, (unknown), Faith Mutale, Rachel Cohen, Corey J. Langer	2
6	Discrepancies of assessments in a RECIST 1.1 phase II clinical trial – association between adjudication rate and variability in images and tumors selection 2018 ·Cancer Imaging ·(unknown), Tracey L. Evans, Catherine Klifa, Ali Guermazi, Sae Rom Hong, Mustapha Chadjaa, (unknown)	26
7	A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations 2017 ·Clinical Cancer Research ·Helena A. Yu, Alexander I. Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey L. Evans, Ronan J. Kelly, (unknown), Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, (unknown), Anne Keating, Geoffrey R. Oxnard	23
8	Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508) 2017 ·Annals of Oncology ·Athanassios Argiris, Ju‐Whei Lee, James Stevenson, (unknown), (unknown), Nicholas W. Choong, Joel Saltzman, (unknown), Richard M. Hansen, Tracey L. Evans, Suresh S. Ramalingam, Joan H. Schiller	14
9	P3.02c-029 Immune-Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) Treated with Nivolumab 2017 ·Journal of Thoracic Oncology ·Shawn Kothari, Stephen Bagley, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey L. Evans, John A. Kosteva, Christine Ciunci, Jeffrey C. Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby‐Sandy, Faith Mutale, Gloria A DiLullo, Roger B. Cohen, Anil Vachani, Corey J. Langer	9
10	Using Maslow's hierarchy to highlight power imbalances between visiting health professional student volunteers and the host community: An applied qualitative study 2017 ·Education for Health ·(unknown), Tracey L. Evans, (unknown), (unknown), (unknown), (unknown), (unknown)	9
11	PUB140 A Pilot Study to Assess Circulating Tumor Cells, Circulating Tumor Cell DNA and Cell Free DNA in Patients with Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·Charu Aggarwal, Sunita Badola, Hyunjin Shin, (unknown), (unknown), (unknown), (unknown), Jeffrey Ecsedy, Tracey L. Evans, Joshua Bauml, Roger B. Cohen, Anil Vachani, Corey J. Langer, Huifeng Niu	1
12	P3.02c-028 Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC) 2017 ·Journal of Thoracic Oncology ·Stephen Bagley, Shawn Kothari, Charu Aggarwal, Joshua Bauml, Evan Alley, Tracey L. Evans, John A. Kosteva, Christine Ciunci, Jeffrey C. Thompson, Susan Stonehouse-Lee, Victoria Sherry, Elizabeth Gilbert, Beth Eaby‐Sandy, Faith Mutale, Gloria A DiLullo, Roger B. Cohen, Anil Vachani, Corey J. Langer	4
13	Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement 2016 ·Journal of Oncology Practice ·Kathleen Bickel, Kristen K. McNiff, Mary K. Buss, Arif H. Kamal, Dale Lupu, Amy P. Abernethy, Michael S. Broder, Charles L. Shapiro, (unknown), Jennifer L. Malin, Tracey L. Evans, Monika K. Krzyzanowska	107
14	Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status 2015 ·Tracey L. Evans	1
15	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma 2014 ·Autophagy ·Reshma Rangwala, Robert D. Leone, Yunyoung C Chang, Leslie A. Fecher, Lynn M. Schuchter, Amy Kramer, (unknown), Daniel F. Heitjan, (unknown), Maryann Gallagher, Shengfu Piao, Andrea B. Troxel, Tracey L. Evans, Angela DeMichele, Katherine L. Nathanson, Peter J. O’Dwyer, (unknown), Laura Pontiggia, Lisa E. Davis, Ravi K. Amaravadi	294
16	Complementary and Alternative Medicine Use and Benefit Finding Among Cancer Patients 2013 ·The Journal of Alternative and Complementary Medicine ·Sheila N. Garland, (unknown), Krupali Desai, Susan Li, Corey J. Langer, Tracey L. Evans, Jun J. Mao	57
17	Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies 2013 ·Clinical Lung Cancer ·Joshua Bauml, Rosemarie Mick, Yu Zhang, Christopher D. Watt, Anil Vachani, Charu Aggarwal, Tracey L. Evans, Corey J. Langer	37
18	A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Toxicities and Clinical Response 2012 ·Journal of Thoracic Oncology ·Ramesh Rengan, Rosemarie Mick, Daniel A. Pryma, Mark Rosen, Lilie L. Lin, Amit Maity, Tracey L. Evans, James Stevenson, Corey J. Langer, John C. Kucharczuk, Joseph S. Friedberg, (unknown), Tiffany Sharkoski, Stephen M. Hahn	59
19	Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Single-Institution Experience 2010 ·Clinical Lung Cancer ·Binu Malhotra, Tracey L. Evans, Jared Weiss, Beth Eaby, Susan Stonehouse-Lee, Victoria Sherry, Corey J. Langer	10
20	Chemotherapy in Advanced Non-Small Cell Lung Cancer 2005 ·Seminars in Respiratory and Critical Care Medicine ·Tracey L. Evans	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact